Rhythm Pharmaceuticals (RYTM) Other financing activities (2018 - 2026)

Rhythm Pharmaceuticals (RYTM) has 9 years of Other financing activities data on file, last reported at $1.3 million in Q1 2026.

• On a quarterly basis, Other financing activities rose 46.49% year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $189.1 million, a 5458.78% increase from a year earlier, with the FY2025 full-year figure at $188.7 million, up 2019.74% from the prior year.
• Other financing activities for Q1 2026 stood at $1.3 million, down from $177.5 million in the prior quarter.
• Over the last five years, Other financing activities for RYTM reached as high as $177.5 million in Q4 2025 and fell as low as -$6.5 million in Q3 2024.
• Historically, Other financing activities has averaged $12.5 million across 5 years, with a median of $1.3 million in 2024.
• Across the five-year window, Other financing activities sank 511.22% in 2024 and soared 2226.37% in 2025, its largest moves.
• Year by year, Other financing activities stood at -$3.2 million in 2022, then increased by 23.66% to -$2.5 million in 2023, then surged by 408.78% to $7.6 million in 2024, then surged by 2226.37% to $177.5 million in 2025, then plunged by 99.3% to $1.3 million in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $1.3 million in Q1 2026, $177.5 million in Q4 2025, and $5.5 million in Q3 2025.